Fig. 3: Myeloid Wnt5a promotes biliary scar deposition.

a mRNA expression of Wnt5a in whole liver from mice with either DDC (left panel) or TAA (right panel) induced biliary disease. b Immunofluorescence showing the localisation of WNT5A protein (red) to CD68-positive cells (green, left panel), not αSMA-positive cells (green, right panel), yellow arrows show dual-positive cells. c mRNA from DDC-treated mice showing loss of Wnt-PCP target genes, Ctgf and Mmp7, normalised to Ppia in isolated bile ducts following deletion of Wnt5a from monocyte lineages. d Histological quantification of Keratin-19 (biliary epithelial cells), Desmin (fibroblasts), Picrosirius Red, PSR (fibrillar collagens) and Collagen-1 in livers of mice treated with DDC following myeloid-specific deletion of Wnt5a. e mRNA from TAA-treated mice showing loss of Wnt-PCP target genes, Ctgf and Mmp7 normalised to Ppia in isolated bile ducts following deletion of Wnt5a from monocyte lineages. f Histological quantification of Keratin-19 (biliary epithelial cells), Desmin (fibroblasts), Picrosirius Red, PSR (fibrillar collagens) and Collagen-1 in livers of mice treated with TAA following myeloid-specific deletion of Wnt5a. Scale bar = 50 µm. Source data are provided as a Source Data file. In graphs where two groups are included, a Student’s t test is used. Box–whisker plots represent min–max range of the data. In dot plots, data are presented as mean ± S.E.M. Each data point (N) represents an individual animal.